CompletedNCT06229977
A Trial of the Fatty Acid Amide Hydrolase Inhibitor Palmitoylethanolamide in Depression in bipolarity
Medication studyAges 18–70United States
Understand this study
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 70 years. Other eligibility criteria applied.
- Listed locations
- HoustonSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: May 17, 2023
- Recruitment status
- Completed
- Enrollment listed in the registry
- 34
- Sponsor
- Rodrigo Machado-Vieira, MD, PhD, MSc
- Sponsor type
- Individual investigator
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 70 Years
- Official registry ID
- NCT06229977
- Official title
Show the full official title
A Randomized Controlled Trial of the Fatty Acid Amide Hydrolase Inhibitor Palmitoylethanolamide in Bipolar Depression
Get this study by email
Recruitment & locations
CompletedHouston
Questions about this study
Who is behind this study?
The study sponsor is Rodrigo Machado-Vieira, MD, PhD, MSc.
Did this study involve medication?
Yes. The study involved medication, including Palmitoylethanolamide (PEA) and Placebo.
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 70 years. Other eligibility criteria applied.
